An important step in moving novel neuroprotective agents
towards the clinic involves testing the efficacy of therapeutics in preclinical
models. Many different preclinical
models are available ...
As is the case in other diseases, the current gold standard methodology
for testing the efficacy of experimental Parkinson’s disease
therapeutics involves the placebo-controlled study ...
Mutations in the gene coding for the putative kinase LRRK2 represent some of the most prevalent genetic factors yet linked to Parkinson’s disease, but how these alterations lead to PD-related ...
There is evidence of oxidative damage in brains of PD patients and anti-oxidant therapies have been explored as disease-modifying therapies for PD. Alpha-synuclein aggregation - in the form of Lewy ...
Current theory suggests a possible toxic oligomeric or aggregated form of alpha-synuclein as the trigger for subsequent neurodegeneration in PD, but definitive evidence for this is lacking. Proposed ...
Widespread availability of critical research tools is necessary for rapid progress in PD research. Researchers may find, however, that the process for doing so can be time-consuming. Distribution of ...
The demonstration that forced expression of only a handful of genes can 'reprogram' adult human skin cells into induced pluripotent stem (iPS) cells (with properties of embryonic stem cells) has ...
The direct delivery of proteins and genes to the brain by surgical techniques is hampered by the limited diffusion of the molecules into the target area. Convection Enhanced Delivery utilizes ...
PD therapeutics development presents many trial design challenges, such as, for example, the difficulty of measuring changes in disease progression, and the inherent variability in clinical ...
The decision by Amgen to halt the GDNF human trials was met with controversy and a vocal response from the patient community. While some serious concerns were raised regarding the safety of ...